PROLLENIUM® Launches VAMP™ Advanced, a Patent-Pending PDRN SolutionA high concentration medical-grade polydeoxyribonucleotide (PDRN) formulation designed for advanced skin rejuvenation
PROLLENIUM® Names Erick Brenner as Chief Executive Officer
PROLLENIUM® Medical Technologies, a privately held medical aesthetics company, has appointed Erick Brenner as Chief Executive Officer, effective immediately. Brenner succeeds Walter Geiger, who has served as Interim CEO since April 2025, and will return to his role as Operating Partner at ARCHIMED, PROLLENIUM®’s majority shareholder.
PROLLENIUM® Named Industry Partner of the Year at Aesthetic Next 2025
PROLLENIUM®, a pioneer in regenerative and medical aesthetics, has been recognized as the Industry Partner of the Year at the Aesthetic Next 2025 conference. The award acknowledges PROLLENIUM®’s unwavering commitment to innovation, education, and collaborative partnership within the aesthetic community.
